Karman Holdings Inc.
KRMN
$36.65
+5.99%
Karman Holdings Inc. designs, tests, manufactures, and sells mission-critical systems for missile and defense and space programs, organized into three engineered solution families: Payload Protection and Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company is a niche, highly engineered supplier to the U.S. Department of Defense and space launch ecosystem, with exposure to three growing end markets — Hypersonics & Strategic Missile Defense, Missile & Integrated Defense Systems, and Space & Launch — positioning it as a pure-play beneficiary of geopolitical rearmament and launch-capacity scarcity rather than a broad prime contractor. The investor narrative has swung violently since its February 2025 IPO: a defense-spending tailwind and record Q1 2026 results (with a reported $1 billion backlog and raised guidance) initially drove the stock to a 52-week high of $118.38, but a short-seller report questioning its acquisition strategy and valuation, combined with a sharp deceleration in the share price, has turned the debate toward whether the roll-up model and premium multiple can be sustained. Attention now centers on the credibility of the M&A-driven growth story, the company's ability to convert strong revenue growth into free cash flow, and whether the recent selloff represents a durable value opportunity or a structural de-rating.…
KRMN
Karman Holdings Inc.
$36.65
Related headlines
Investment Opinion: Should I buy KRMN Today?
Rating: Hold (speculative). The core thesis is that Karman's 58.18% revenue growth, 42.97% gross margin, $1 billion backlog, and unanimous strong-buy consensus with a $81.75 average target imply enormous upside, but negative free cash flow of -$27.67 million and a 562.8x trailing PE mean the risk/reward is not yet favorable for most investors. The analyst consensus rating of 1.31 (strong buy) and average target of $81.75 (+135.7% upside) anchor a bullish view, but the market's refusal to converge toward those targets signals that price discovery remains inefficient and volatility elevated.
Supporting evidence for a constructive stance includes: revenue growth of 58.18% YoY in Q2 2026 versus $115.10 million in Q2 2025; gross margin expansion from 39.86% in Q4 2025 to 42.97% in Q2 2026; operating margin of 19.13%; and a forward PE of 36.5x versus trailing PE of 562.8x, implying the market expects earnings to multiply roughly 15-fold over the next twelve months. However, PS of 20.53x, EV/Sales of 9.02x, and EV/EBITDA of 85.4x remain far above typical aerospace and defense ranges of 2x-5x EV/Sales, and trailing free cash flow of -$27.67 million confirms the company is not yet self-funding.
The biggest risks that could invalidate the thesis are: (1) the short-seller report gaining credibility and forcing a restatement or strategic pivot; (2) free cash flow remaining negative as working capital and interest costs consume operating cash; and (3) a breakdown below the $29.34 52-week low triggering further momentum selling. This Hold would upgrade to Buy if free cash flow turns positive for two consecutive quarters and the stock reclaims the $40-$45 resistance zone, or downgrade to Sell if revenue growth decelerates below 30% or the stock breaks below $29.34. On valuation, the stock is fairly valued to slightly overvalued relative to its own compressed history but still expensive in absolute terms — the market has repriced growth expectations but not fully normalized them.
Sign up to view all
KRMN 12-Month Price Forecast
The forward view is genuinely balanced: the growth trajectory (58.18% YoY revenue, 42.97% gross margin) and analyst conviction (12 analysts, 1.31 mean rating, $81.75 average target) are powerful, but the cash flow profile (-$27.67 million trailing FCF) and leverage (1.53x debt-to-equity, 2.28x interest coverage) mean the thesis depends on an earnings inflection that has not yet materialized. The 562.8x trailing PE versus 36.5x forward PE is the single most important valuation fact — it prices in a dramatic margin inflection as acquisition integration and interest costs normalize, and any delay in that inflection would be punished severely. I would upgrade to bullish if the company reports positive free cash flow and breaks out segment organic growth, and downgrade to bearish if the stock breaks below $29.34 or the short-seller allegations escalate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Karman Holdings Inc.'s 12-month outlook, with a consensus price target around $78.54 and implied upside of +114.3% versus the current price.
Average Target
$78.54
0 analysts
Implied Upside
+114.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $100
Analyst target range
Coverage is robust for a recent IPO, with 12 analysts and a consensus recommendation of "strong buy" (mean rating of 1.31 on a 1-to-5 scale where 1 is a strong buy). The average target price is $81.75, implying roughly +135.7% upside from the current $34.68 — an unusually wide gap that reflects either significant analyst lag in updating models after the selloff or genuine conviction that the decline is overdone. The consensus clearly leans bullish, and the institutional ratings history shows a striking pattern of reiterations rather than downgrades: RBC Capital maintained Outperform on September 28, 2026, Truist maintained Buy on August 13, Citigroup maintained Buy on August 10, and Piper Sandler, Evercore ISI, and Needham all reiterated Buy/Overweight ratings in early August — with BWS Financial the lone Sell. The target range of $63.00 to $100.00 is wide, signaling high uncertainty: the $100 high target likely assumes successful acquisition integration, margin expansion toward the mid-20s operating level, and multiple re-rating as hypersonics and missile-defense budgets accelerate, while the $63 low still implies +81.7% upside and appears to price in slower growth and continued cash burn rather than a bear-case collapse. The fact that even the lowest target sits far above the current price, combined with unanimous reiterations and a short ratio of 3.79, suggests analysts view the short-seller-driven selloff as a dislocation — but the market's refusal to converge toward targets is a warning that price discovery remains inefficient and volatility elevated.
Bulls vs Bears: KRMN Investment Factors
The bear case currently has stronger near-term evidence: negative free cash flow of -$27.67 million, interest expense consuming 79% of pre-tax income, a 562.8x trailing PE, and a -70.40 percentage point one-year relative strength gap versus SPY are hard, quantifiable facts. The bull case rests on genuinely impressive 58.18% revenue growth, expanding gross margins (42.97%), a $1 billion backlog, and a unanimous strong-buy analyst consensus with a $81.75 average target implying +135.7% upside. The single most important tension is whether Karman's growth is durable organic demand from hypersonics, missile defense, and space programs or largely inorganic roll-up arithmetic funded by debt — a question the company's lack of segment disclosure makes impossible to answer definitively. If organic growth and free cash flow inflect positively, the stock is deeply undervalued; if the roll-up model is questioned further or cash burn persists, the premium multiple has much further to compress.
Bullish
- Revenue growth accelerating at 58% YoY: Q2 2026 revenue of $182.06 million grew 58.18% year-over-year versus $115.10 million in Q2 2025, with sequential expansion from $121.79M (Q3 2025) to $134.49M (Q4 2025) to $151.21M (Q1 2026) to $182.06M (Q2 2026). This is consistent double-digit sequential growth, not a one-quarter spike.
- Analyst consensus strong buy, 136% upside: All 12 covering analysts have a mean rating of 1.31 (strong buy) with an average target of $81.75, implying +135.7% upside from $34.68. Even the lowest target of $63.00 implies +81.7% upside, and RBC, Truist, Citigroup, Piper Sandler, Evercore ISI, and Needham have all reiterated Buy/Overweight ratings through August-September 2026.
- Gross margin expanding on mix: Gross margin rose from 39.86% in Q4 2025 to 42.24% in Q1 2026 to 42.97% in Q2 2026, and operating margin reached 19.13% in Q2 2026. This suggests pricing power and favorable mix in hypersonics, missile defense, and space programs rather than purely acquired low-margin revenue.
- Deep value positioning after 74% drawdown: At $34.68 the stock sits at roughly 5.9% of its 52-week range ($29.34-$118.38) after a -73.86% maximum drawdown, while the 1-month decline (-6.12%) is far milder than the 3-month (-24.89%) and 6-month (-58.51%) declines. The decelerating pace of selling plus a 3.79 short ratio creates squeeze potential on any positive catalyst.
Bearish
- Negative free cash flow and cash burn: Trailing free cash flow is -$27.67 million, Q2 2026 operating cash flow was -$3.18 million against $14.49 million of capex, and working capital consumed $34.70 million in the quarter with days sales outstanding at 149 days. Growth is being funded by debt and equity issuance, not internal cash generation.
- Extreme valuation on every metric: Trailing PE is 562.8x, PS is 20.53x, EV/Sales is 9.02x, EV/EBITDA is 85.4x, PEG is 15.96, and price-to-book is 25.30x. Even after multiple compression from PS of 71.99x at year-end 2025, the stock remains far above typical aerospace and defense ranges of 15x-30x PE and 2x-5x EV/Sales.
- Leverage consumes nearly all pre-tax income: Debt-to-equity is 1.53x, total debt to capitalization is 67.5%, and interest coverage is only 2.28x. Q2 2026 interest expense of $15.28 million consumed roughly 79% of pre-tax income of $19.27 million, leaving EPS at just $0.11 and net margin at 7.71%.
- Short-seller report questions roll-up model: A short-seller report questioning Karman's acquisition strategy and valuation has driven the recent selloff, and the company does not break out segment revenue, limiting visibility into organic versus acquired growth. Q1 2026 acquisition spending of $210.15 million is central to the bull case but also the core of the bear thesis.
KRMN Technical Analysis
Karman is in a severe, sustained downtrend: the stock is down 54.87% over the past year and 58.51% over six months, with a maximum drawdown of -73.86% from its peak. At $34.68, the shares sit at roughly 5.9% of the 52-week range between the $29.34 low and $118.38 high — a positioning that reflects capitulation rather than momentum, and one that historically signals either deep value or a falling knife depending on fundamental stabilization. The 1-year relative strength versus SPY is -70.40 percentage points, underscoring how decisively the market has abandoned this name relative to a benchmark that gained 15.53% over the same period. Short-term momentum remains negative but is decelerating in severity: the stock is down 6.12% over one month and 24.89% over three months, versus a 1.22% gain and 2.69% gain for SPY, respectively, producing relative strength readings of -7.34 (1-month) and -27.58 (3-month). The 1-month decline is materially smaller than the 3-month and 6-month declines, suggesting the pace of selling is moderating even as the primary trend stays down — a potential early mean-reversion signal, though not yet a confirmed reversal. The most recent sessions show a modest bounce, with the stock up 2.30% on the day from $33.90 to $34.68 and up from the $30.14 close on October 14, indicating buyers are defending the low-$30s. Key technical support sits at the 52-week low of $29.34; a breakdown below that level would confirm the downtrend and likely trigger further momentum-driven selling toward new all-time lows. Resistance is defined by the 52-week high of $118.38, but more practically by the $40–$45 zone where the stock repeatedly stalled in September; reclaiming that band would be the first evidence of a trend change. With a short ratio of 3.79 and volume of roughly 7.0 million shares, the elevated short interest raises the possibility of sharp squeeze-driven rallies on any positive catalyst, but also amplifies downside volatility if support fails.
Beta
—
—
Max Drawdown
-73.9%
Largest decline past year
52-Week Range
$29-$118
Price range past year
Annual Return
-55.3%
Cumulative gain past year
| Period | KRMN Return | S&P 500 |
|---|---|---|
| 1m | +10.9% | -1.0% |
| 3m | -22.7% | +2.9% |
| 6m | -47.8% | +6.5% |
| 1y | -55.3% | +13.1% |
| ytd | -52.3% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KRMN Fundamental Analysis
Revenue growth is genuinely strong and accelerating: Q2 2026 revenue of $182.06 million grew 58.18% year-over-year versus $115.10 million in Q2 2025, and the sequential trajectory from $121.79 million (Q3 2025) to $134.49 million (Q4 2025) to $151.21 million (Q1 2026) to $182.06 million (Q2 2026) shows consistent double-digit sequential expansion. This growth is clearly being amplified by acquisitions — the Q1 2026 cash flow statement shows $210.15 million of acquisition spending — which is central to the bull case but also the focus of short-seller scrutiny. The investment case hinges on whether this is durable organic demand from hypersonics, missile defense, and space programs or largely inorganic roll-up arithmetic; the company does not break out segment revenue, limiting visibility. Profitability is improving but thin at the bottom line: Q2 2026 net income was $14.03 million on a 7.71% net margin, with gross margin of 42.97% (up from 40.85% in Q2 2025) and operating margin of 19.13%. Gross margin has expanded steadily from 39.86% in Q4 2025 to 42.24% in Q1 2026 to 42.97% in Q2 2026, a positive mix signal, but interest expense of $15.28 million in Q2 2026 exceeded operating income growth and consumed roughly 79% of pre-tax income, leaving EPS at just $0.11. The balance sheet carries meaningful leverage: debt-to-equity is 1.53x, total debt to capitalization is 67.5%, and interest coverage is only 2.28x, while the current ratio of 3.29x and quick ratio of 3.40x indicate ample near-term liquidity. Cash generation is the weak link — trailing free cash flow is -$27.67 million, Q2 2026 operating cash flow was -$3.18 million against $14.49 million of capex, and working capital consumed $34.70 million in the quarter, largely receivables (days sales outstanding of 149 days). ROE of 4.54% and ROA of 5.14% are low for a company trading at this valuation, and the negative FCF yield means growth is currently being funded by debt and equity issuance rather than internal cash generation.
Quarterly Revenue
$182063000.0B
2026-06
Revenue YoY Growth
+58.2%
YoY Comparison
Gross Margin
43.0%
Latest Quarter
Free Cash Flow
$-27671000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KRMN Overvalued?
Because net income is positive ($14.03 million in Q2 2026), the PE ratio is the appropriate primary metric, but it is nearly meaningless at current levels: the trailing PE is 562.8x against a forward PE of 36.5x, an extraordinary gap that implies the market expects earnings to multiply roughly 15-fold over the next twelve months. That gap is the single most important valuation fact about this stock — it prices in either a dramatic margin inflection as acquisition integration and interest costs normalize, or it reflects a trailing earnings base distorted by one-time items and heavy interest expense. On sales-based metrics the stock is also expensive but less extreme: PS is 20.53x, EV/Sales is 9.02x, and EV/EBITDA is 85.4x, while the PEG ratio of 15.96 and price-to-book of 25.30x signal that investors are paying heavily for growth and intangible-heavy assets. Peer comparison is constrained because the provided valuation data contains no explicit industry averages; however, aerospace and defense primes and high-growth defense suppliers typically trade in the 15x–30x PE and 2x–5x EV/Sales range, implying Karman's 9.02x EV/Sales and 85.4x EV/EBITDA represent a substantial premium that can only be justified by its 58% revenue growth and hypersonics/space exposure. Historically, the stock's own multiples have compressed dramatically: PS was 71.99x at year-end 2025, 70.16x in Q1 2026, and 36.34x in Q2 2026, while PE fell from 313.8x to 113.5x over the same span — a de-rating driven by both multiple compression and earnings growth. Even after that compression, the current 20.53x PS remains far above the 43x–78x historical band's midpoint only because the stock price collapsed; the multiple is still rich in absolute terms, suggesting the market has repriced growth expectations but not fully normalized them.
PE
562.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 113x~439x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
85.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial and quantifiable. Trailing free cash flow is -$27.67 million, Q2 2026 operating cash flow was -$3.18 million against $14.49 million of capex, and working capital consumed $34.70 million in the quarter with days sales outstanding at 149 days — meaning growth is being funded externally. Leverage is meaningful: debt-to-equity of 1.53x, total debt to capitalization of 67.5%, and interest coverage of only 2.28x, with Q2 2026 interest expense of $15.28 million consuming roughly 79% of pre-tax income and leaving EPS at $0.11. Revenue concentration is also a risk: the company does not break out segment revenue, so investors cannot verify how much of the 58.18% YoY growth is organic versus acquired, and Q1 2026 acquisition spending of $210.15 million makes integration execution critical.
Market and competitive risks center on valuation compression. At a 562.8x trailing PE, 20.53x PS, 9.02x EV/Sales, and 85.4x EV/EBITDA, Karman trades at a substantial premium to typical aerospace and defense ranges of 15x-30x PE and 2x-5x EV/Sales, leaving little room for disappointment. The short-seller report questioning the acquisition strategy and valuation has already triggered a -73.86% maximum drawdown, and the stock's -70.40 percentage point one-year relative strength gap versus SPY shows how violently the market has de-rated the name. Competitive disruption risk is moderate given the niche, highly engineered nature of payload protection, interstage, and propulsion systems, but the company remains exposed to DoD budget priorities and program timing; geopolitical escalation (Iran tensions in February-March 2026) has been a tailwind, but a shift toward de-escalation or defense budget scrutiny would remove that support.
The worst-case scenario is a chain of events in which the short-seller allegations gain credibility, the company fails to break out organic growth or improve free cash flow, and a breakdown below the $29.34 52-week low triggers momentum-driven selling toward new all-time lows. From the current $34.68, a move to the 52-week low of $29.34 represents roughly -15.4%, while a retest of the -73.86% maximum drawdown from the $118.38 peak would imply a price near $30.94 — already close to current levels, meaning the stock has largely priced in a severe outcome. However, if the bear case fully materializes with multiple compression toward peer EV/Sales of 2x-5x, the downside could extend well below $29.34, and the $63.00 analyst low target (still +81.7% above current) would likely be revised sharply lower.
FAQ
The most severe risk is financial: trailing free cash flow of -$27.67 million, Q2 2026 operating cash flow of -$3.18 million, and interest expense of $15.28 million consuming 79% of pre-tax income mean the company is not self-funding and depends on external capital. Second is company-specific: the short-seller report questioning the acquisition strategy and valuation has already driven a -73.86% maximum drawdown, and the lack of segment revenue disclosure limits visibility into organic versus acquired growth. Third is valuation compression: at 20.53x PS and 85.4x EV/EBITDA, the stock has little room for disappointment, and a break below the $29.34 52-week low would trigger momentum selling. Fourth is macro and competitive: DoD budget priorities, program timing, and geopolitical de-escalation could remove the defense tailwind that has supported the stock.
The 12-month forecast has three scenarios: a 25% probability bull case targeting $81.75-$100.00 (analyst average to high target), a 50% probability base case targeting $45.00-$63.00 (stabilization below the analyst low target), and a 25% probability bear case targeting $20.00-$29.34 (breakdown below the 52-week low). The base case is most likely, assuming revenue growth decelerates from 58% toward 30-40% as acquisition comps normalize, free cash flow remains negative or breakeven, and no major new short-seller allegations emerge. The key assumption behind the base case is that the company neither fully rebuts nor validates the short-seller thesis, leaving the stock in a volatile range below analyst targets.
KRMN is expensive in absolute terms but has compressed dramatically from its own history. The trailing PE of 562.8x, PS of 20.53x, EV/Sales of 9.02x, EV/EBITDA of 85.4x, PEG of 15.96, and price-to-book of 25.30x are all far above typical aerospace and defense ranges of 15x-30x PE and 2x-5x EV/Sales. However, PS has fallen from 71.99x at year-end 2025 to 20.53x now, and PE from 313.8x to 562.8x (distorted by interest expense), showing significant de-rating. The forward PE of 36.5x versus trailing PE of 562.8x implies the market expects earnings to multiply roughly 15-fold over the next twelve months. The market is paying a premium that can only be justified by the 58.18% revenue growth and hypersonics/space exposure — the stock is fairly valued to slightly overvalued relative to its compressed history but still rich in absolute terms.
From a risk/reward perspective, KRMN offers exceptional upside if the bull case materializes: the $81.75 average analyst target implies +135.7% upside from $34.68, and even the $63.00 low target implies +81.7%. However, the downside risk is equally real — trailing free cash flow is -$27.67 million, interest coverage is only 2.28x, and a break below the $29.34 52-week low would imply roughly -15.4% from current levels with potential for further decline. The 562.8x trailing PE versus 36.5x forward PE means the market is pricing in a dramatic earnings inflection that has not yet occurred. This is a good buy only for risk-tolerant investors with a multi-year horizon who can withstand significant volatility and who believe the short-seller allegations will be rebutted; for conservative investors, the cash burn and leverage make it unsuitable.
KRMN is suitable primarily for long-term, risk-tolerant growth investors, not short-term traders. The company is in an early growth stage (IPO in February 2025), pays no dividend (payout ratio of 0), and has negative free cash flow of -$27.67 million, meaning earnings visibility is low and the stock is highly volatile — it has a -73.86% maximum drawdown and a -70.40 percentage point one-year relative strength gap versus SPY. The 3.79 short ratio creates short-term squeeze potential, but the primary trend remains down and the stock is down 54.87% over one year. A concrete suggested minimum holding period is 2-3 years, allowing time for acquisition integration, free cash flow inflection, and multiple normalization; short-term trading should be avoided given the elevated volatility and binary short-seller risk.